Secondary endpoint analyses—efficacy outcome measures
| Ozurdex+laser N=40 | Number missing | Laser N=40 | Number missing | Effect estimate | 95% CI | |
|---|---|---|---|---|---|---|
| Patients gaining ≥10 ETDRS letters at 56 weeks from baseline, n (%) | 7 (18.4) | 2 | 8 (20.5) | 1 | 1.14 | 0.37 to 3.54 |
| Patients gaining ≥15 ETDRS letters at 56 weeks from baseline, n (%) | 6 (15.8) | 2 | 2 (5.1) | 1 | 0.29 | 0.05 to 1.53 |
| Patients losing <15 ETDRS letters at 56 weeks from baseline, n (%) | 35 (92.1) | 2 | 35 (89.7) | 1 | ||
| Patients losing ≥30 ETDRS letters at 56 weeks from baseline, n (%) | 1 (2.6) | 2 | 0 (0.0) | 1 | – | – |
| Change in ETDRS BCVA at 24 weeks from baseline, mean (SD) | 1.3 (8.8) | 4 | −0.7 (6.3) | 5 | −1.32 | −4.42 to 1.78 |
| Change in ETDRS BCVA at 40 weeks from baseline, mean (SD) | −1.1 (12.8) | 8 | −0.1 (6.8) | 8 | 1.13 | −3.37 to 5.64 |
All percentages are out of N minus number missing.
BCVA, best-corrected visual acuity; n, number of participants/eyes; N, total number of patients/eyes.